Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanFRA:L74 -4.46%55 EPS without NRI is €0.17 as of Dec. 2025. GuruFocus rates FRA:L74 with a GF Score™ of 55/100. The stock has 3 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 93.75% on this metric.
WuXi XDC Cayman's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €0.07.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.17.
During the past 12 months, WuXi XDC Cayman's average earnings per share (NRI) Growth Rate was 34.20% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 74.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 126.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for WuXi XDC Cayman's EPS without NRI or its related term are showing as below:
FRA:L74'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 74.4 Med: 152 Max: 157.4
Current: 74.4
During the past 6 years, WuXi XDC Cayman's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 157.40% per year. The lowest was 74.40% per year. And the median was 152.00% per year.
FRA:L74's 3-Year EPS without NRI Growth Rate is ranked better than 93.75% of 160
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.75
vs FRA:L74: 74.40
WuXi XDC Cayman's EPS (Diluted) for the
six
months ended in Dec. 2025 was €0.07.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.14.
WuXi XDC Cayman's EPS (Basic) for the
six
months ended in Dec. 2025 was €0.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.16.
WuXi XDC Cayman (FRA:L74) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
WuXi XDC Cayman EPS without NRI Related Terms
WuXi XDC Cayman EPS without NRI Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:L74 vs TMO, DHR, NTRA: EPS without NRI Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (FRA:L74) has a EPS without NRI of €0.17 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on WuXi XDC Cayman and its competitors. According to the industry distribution chart, WuXi XDC Cayman ranks #10 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is WuXi XDC Cayman's EPS without NRI too high?
WuXi XDC Cayman's current EPS without NRI is €0.17. Based on the distribution chart, WuXi XDC Cayman ranks #10 out of 160 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #10 out of 160 companies for EPS without NRI. This places WuXi XDC Cayman in the top 6% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.75, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EPS without NRI is €0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (FRA:L74) has a current EPS without NRI of €0.17. The current EPS without NRI is €0.17. WuXi XDC Cayman's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For WuXi XDC Cayman (FRA:L74), the current EPS without NRI is €0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
55GF Score
Get the complete analysis for FRA:L74
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L74 has been successfully added to your 
